It has been demonstrated that sleep disorders (SDOs) are associated with the prevalence of nocturia in men. While previous literature supports that patients with obstructive sleep apnea (OSA), insomnia, and restless leg syndrome (RLS) are at increased risk of nocturia, the risk of daytime lower urinary tract symptoms (LUTS) in these groups has not been established. We sought to investigate the frequency of LUTS in men with and without different types of SDO.
INTRODUCTION AND OBJECTIVES:
It has been demonstrated that sleep disorders (SDOs) are associated with the prevalence of nocturia in men. While previous literature supports that patients with obstructive sleep apnea (OSA), insomnia, and restless leg syndrome (RLS) are at increased risk of nocturia, the risk of daytime lower urinary tract symptoms (LUTS) in these groups has not been established. We sought to investigate the frequency of LUTS in men with and without different types of SDO.
METHODS: We examined the National Health and Nutrition Examination Survey (NHANES) database between 2006-2008. Men age 18-70 years who completed the sleep questionnaires in addition to the prostate and kidney forms were included in the study. LUTS was defined as having one more of the following symptoms: hesitancy, incomplete emptying, or nocturia (>¼2). Physician-diagnosed SDOs were self reported by patients. Statistical analyses were used to compare groups of men with and without a SDO.
RESULTS: Of the 6185 men who completed all of the survey questions, 437 (7.1%) men reported a SDO. The clinical characteristics of men with and without a SDO are shown in Table 1 . Men with SDOs were significantly older and significantly more likely to be Caucasian, have increased BMI and report more medical co-morbidities compared to men without SDOs. There was a significantly higher proportion of men with SDOs who reported nocturia compared to those without SDOs (39% vs 27.7%; p <.0001). Additionally, these men had a significantly higher risk of LUTS (including daytime LUTS) than men without SDOs (34.4% vs 22.8%, p <.0001). Men with OSA (31.7%) were significantly more likely to report >¼2 LUTS compared to men with insomnia (18.2%) or RLS (12.5%) (p¼.0002).
CONCLUSIONS: Older age, Caucasian race, elevated BMI, and increased comorbidity score appear to be associated with an increased risk of LUTS in men with SDOs. While men with SDOs report increased nocturia, they are also more likely to experience bothersome daytime LUTS. This is particularly relevant for men with OSA compared to other SDOs. Based upon the present data, clinicians should consider assessing LUTS in men with SDOs as intervention could improve both nighttime and daytime urinary symptoms.
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MP13-16 FACTORS THAT PREDISPOSE TO LOWER URINARY TRACT SYMPTOMS IN DIABETIC MEN: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES)
Richard Fantus*, Chicago, IL; Brian Helfand, Chi-Hsiung Wang, Evanston, IL; Brad Erickson, Iowa City, IA INTRODUCTION AND OBJECTIVES: It has been well established that diabetes mellitus (DM) is a significant risk factor for lower urinary tract symptoms (LUTS). However, data suggests that only approximately 50% of diabetics report bothersome LUTS. We sought to investigate the clinical characteristics that contribute to LUTS in men with diabetes.
METHODS: The 2001-2008 National Health and Nutrition Examination Survey (NHANES) database was examined. The records of men age 18-70 years who completed the diabetes form in addition to the prostate and kidney forms were analyzed. LUTS was defined as having one or more of the following symptoms: hesitancy, incomplete emptying, or nocturia >¼2). Patients' diabetes status, clinical characteristics and laboratory values were recorded. Statistical analyses was used to compare the frequency of clinical variables among diabetics with and without LUTS.
RESULTS: 19202 patients met inclusion criteria including 1157 (6%) with DM. DM patients were significantly more likely to report hesitancy (12.2% vs 9.5%, p¼0.012), nocturia (50.1% vs 25.4%, p<.001) but not incomplete emptying (83.6% vs 86.5%, p¼.024) compared to non-DM patients. Diabetic men with LUTS were significantly older (63.5 vs 57.5 years, p<.001), more likely to be Caucasian (45.5% vs 28.2%, p¼0.002) and more likely to report more medical co-morbidities (32% vs 29.1%, p¼<.001) compared to non-DM patients without LUTS. Insulin did not alter the frequency of LUTS among DM patients (p>.05). Diabetic men with retinopathy were significantly more likely to report urinary hesitancy (38.9% vs 21.8%, p<.001), but significantly less likely to report incomplete emptying (21.9% vs 78.1%, p¼.004) and >¼2 different LUTS (23.1% Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e159 vs 76.9%, p¼.013). There was a similar trend in patients with diabetic nephropathy (defined as significant proteinuria) as shown in Table 1 . CONCLUSIONS: Increased age, Caucasian race and more medical co-morbidities are associated with an increased risk of LUTS in men with DM. While diabetics with evidence of end organ damage report an increase in specific urinary symptoms, they report fewer total number of LUTS. This data demonstrates the importance of screening diabetics for LUTS and suggests specific LUTS may be a harbinger of clinical deterioration in these patients. (BPH) . While the procedure routinely involves urethral catheter placement, no guidelines exist to inform the duration of catheter use. For these reasons, we formally assessed the appropriateness of different timings for urethral catheter removal after transurethral resection or ablation of the prostate using the RAND/UCLA Appropriateness Method.
Source of
METHODS: An 11-member expert panel reviewed a summary of the literature on this topic. Using a standardized, multi-round rating process from March through May 2015, the panel rated clinical scenarios for urethral catheter duration as appropriate (i.e., benefits outweigh risks), inappropriate, or of uncertain appropriateness. The appropriateness of various urethral catheter durations was examined across 4 clinical scenarios.
RESULTS: Forty-four articles met inclusion criteria for our study (Figure) . Based on our expert panel ratings (Table) , urethral catheter removal and first trial of void on postoperative day 1 was appropriate for all scenarios except clinically-significant perforations. In this case, waiting until postoperative day 3 was deemed the earliest appropriate timing. Perforation was the only appropriate indication for waiting 7 days after surgery for initial catheter removal and trial of void. Waiting 3 days to remove the catheter for patients with or without pre-existing catheter needs, or for those with difficult catheter placement in the operating room, was rated as inappropriate.
CONCLUSIONS: We defined clinically-relevant guidance statements for the appropriateness of urethral catheter duration after transurethral prostate surgery. Given the lack of guidelines for catheter duration and this robust expert panel approach, our findings may serve to improve the consistency and quality of care for patients undergoing transurethral surgery for BPH. METHODS: A total of 11,222 healthy men who received transrectal ultrasonography at our hospital for a routine health check-up were included. Those with prior biopsies or surgery for prostate disease, or with BPH medication were excluded. BPH/LUTS was defined as International Prostate Symptom Score (IPSS)8 points and PV 30 mL.
RESULTS: The prostate-specific antigen (PSA) level, PSA density, PV, transitional zone volume (TV), and transitional zone index (TZI) increased significantly with age. The annual PV growth rate was 0.48 cm
